Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA To Open India Office In December

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - U.S. FDA plans to step up scrutiny of drugs and food made in India for the U.S. market by setting up offices next month in the country after establishing three branches in China, according to U.S. officials

You may also be interested in...



U.S. FDA Commissioner Hamburg Promotes Regulatory Science Collaboration In China Visit

SHANGHAI - China is predicted to become the world's second largest economy by the end of this year, and last week, U.S. FDA Commissioner Margaret Hamburg made her first trip to China to boost communication with China's State FDA and to emphasize that the relationship between the U.S. and China has become more important than ever

U.S. FDA Commissioner Hamburg Promotes Regulatory Science Collaboration In China Visit

SHANGHAI - China is predicted to become the world's second largest economy by the end of this year, and last week, U.S. FDA Commissioner Margaret Hamburg made her first trip to China to boost communication with China's State FDA and to emphasize that the relationship between the U.S. and China has become more important than ever

U.S. FDA’s International Offices To Be Fully Staffed By End Of Summer

By the end of the summer, U.S. FDA will have a permanent staff in its newly opened international offices in China, Europe, India and Latin America

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel